|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche?
Datamonitor, July 2003, Pages: 78
Introduction
The HIV and hepatitis C (HCV) treatment markets are among the fastest growing infectious disease sectors. As co-infection with HIV and HCV is becoming increasingly common, as a result of shared transmission routes, key players are faced with a series of challenges. These include driving compliance rates, overcoming drug interactions, and accessing high risk populations.
Scope
- Key opinion leader insight into treatment strategies for co-infected HIV/HCV patients
- Case studies featuring the leading global players: Roche, GlaxoSmithKline, Boehringer Ingelheim and Gilead
- Key data and detailed epidemiology of HIV and HCV in the seven major markets: the US, Japan, Germany, France, Italy, Spain, and the UK
- Review of current HIV and HCV markets, including key company market share
Report Highlights
HCV is the most prevalent chronic infection within the HIV cohort, infecting over 30% of HIV positive individuals. However, the HIV/HCV co-infected population is primarily comprised of difficult-to-treat patient groups, such as intravenous drug users (IDUs).
HIV/HCV patient potential is limited by poor compliance and low prevalence rates, limiting the incentive for novel product development. However, penetration of the co-infected market will enable companies to leverage their products into the wider HIV or HCV mono-infected populations.
Treatment of HIV/HCV co-infected patients is complicated by drug-drug interactions and the hepatotoxic side effects of certain HIV products. The design and development of a treatment package with proven efficacy in the co-infected population would provide physicians with a convenient treatment strategy.
Reasons to Purchase
- Identification of key co-infected high-risk patient populations will enable companies to design effective targeting strategies
- Evaluation of current treatment practices highlights areas of clinical unmet need and subsequent potential penetration strategies
- Detailed analysis of existing and pipeline products allows identification of opportunities for company collaboration in the co-infection market.
Customers who bought this item also bought
Pipeline Insight: HIV - The Age of Convenience
Strategic Perspectives: Opportunistic Infections in HIV
Commercial Perspectives: Pegylated Interferons - Leading the Way in HCV Therapy?
HIV Update 2001 (4) - Aids Wasting and Lipodystrophy
HIV Update 2002 (7): July
HIV: Future Treatment Directions - A Strategic Analysis of Market Developments and Opportunities
Stakeholder Insight: HIV Therapy Dynamics
Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
Pipeline Insight: HIV - Extending Treatment Options
HIV Update 2002 (5) - May
The Medical Management of HIV/AIDS
|
|
|
|
